Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies

Hélène Rogniaux, Alain Van Dorsselaer, Patrick Barth, J.f. Biellmann, J. Barbanton, M. Van Zandt, Bernard Chevrier, Eduardo Howard, A. Mitschler, Noëlle Potier, Ludmila Urzhumtseva, D. Moras, A. PodjarnyJournal of the American Society for Mass Spectrometry 1999 · DOI

TL;DR

This paper presents a complementary approach to drug discovery by combining X-ray crystallography and mass spectrometry to study aldose reductase inhibitors. They demonstrate that gas-phase stability measurements from mass spectrometry can rapidly assess the electrostatic and hydrogen-bonding interactions of inhibitors with the enzyme, offering a valuable tool for monitoring drug design optimization.

What Problem Does This Paper Address?

Diabetes mellitus is associated with severe degenerative complications, and aldose reductase (AR) is implicated in these issues. Developing specific AR inhibitors is a major pharmaceutical goal. While X-ray crystallography provides detailed structural insights into how inhibitors bind to AR, it's a time-consuming process, making it unsuitable for high-throughput screening of numerous potential drug candidates. The challenge is to find a faster method to evaluate inhibitor binding, particularly focusing on key interactions that can be readily modified during drug design, without sacrificing accuracy.

Methods

The study employs two primary techniques:

  • X-ray Crystallography: This method was used to determine the precise atomic-level interactions between aldose reductase and four different inhibitors (AminoSNM, Imirestat, LCB3071, and IDD384). This provided detailed information about the contacts, including hydrogen bonds and electrostatic interactions, within the enzyme's active site.
  • Electrospray Ionization Mass Spectrometry (ESI-MS): This technique was used to measure the gas-phase stability of noncovalent enzyme-coenzyme-inhibitor complexes. By increasing the accelerating voltage (Vc) in the mass spectrometer's interface region, the researchers induced dissociation of these complexes. The voltage required to dissociate 50% of the complex (Vc50) served as a measure of its gas-phase stability. This method is significantly faster than crystallography.

Datasets

The study used four specific aldose reductase inhibitors: AminoSNM, Imirestat, LCB3071, and IDD384. These inhibitors represent different structural classes and were chosen for their relevance to drug development. The aldose reductase enzyme used was from pig lens and also a recombinant human form, with both showing similar behavior in ESI-MS.

Key Insights and Ideas

  • Mass Spectrometry as a Rapid Screening Tool: The core idea is that gas-phase stability (measured by Vc50) can serve as a proxy for the strength of electrostatic and hydrogen-bonding interactions, which are crucial and readily modifiable during drug design. This allows for rapid screening of many potential inhibitors.
  • Correlation Between Gas-Phase Stability and Electrostatic/H-bond Interactions: The study found a strong correlation between the Vc50 values (gas-phase stability) and the calculated electrostatic and hydrogen-bond binding energies (Eel-H) derived from crystallographic data. This validates the hypothesis that gas-phase stability is largely dictated by these specific interactions.
  • Discrepancy Between Gas-Phase and Solution-Phase Binding: Importantly, the gas-phase stability (Vc50) did not directly correlate with the solution-phase inhibition constants (IC50). This highlights that hydrophobic interactions, which contribute significantly to solution-phase binding but are likely lost in the gas phase, play a different role in each measurement.
  • Complementary Nature of Techniques: The paper strongly advocates for using X-ray crystallography and mass spectrometry in tandem. Crystallography provides the detailed "why" and "how," while mass spectrometry offers a rapid "how much" for specific interaction types, guiding the optimization process.

Key Results

  • Vc50 Values and Stability Ranking: The inhibitors were ranked by gas-phase stability (highest to lowest) as: IDD384 > LCB3071 > Imirestat > AminoSNM. This ranking was consistent with the calculated electrostatic and H-bond binding energies.
  • Correlation Strength: A clear correlation was observed between the calculated Eel-H and the measured VC50 values, supporting the idea that gas-phase stability reflects these specific interactions.
  • Lack of Correlation with IC50: The order of inhibitors based on solution-phase inhibition (IC50) was significantly different from the gas-phase stability order, emphasizing the distinct contributions of hydrophobic forces in solution. For example, IDD384, with a poor hydrophobic interaction, showed high gas-phase stability but lower solution-phase potency compared to LCB3071.

Limitations and Future Work

  • Protein Conformation in Gas Phase: A key limitation acknowledged is that the protein's 3D structure might be altered in the gas phase compared to its solution state. This could affect the active site geometry and thus the measured binding energies. The authors suggest that preliminary verification of structural integrity in the gas phase is necessary for other protein-ligand systems.
  • Hydrophobic Interactions: The study focuses on electrostatic and H-bond interactions, assuming hydrophobic contributions are lost in the gas phase. While this is a strength for monitoring specific modifications, it means gas-phase stability alone cannot fully predict solution-phase binding affinity.
  • Future Work: The authors propose using this complementary approach for drug design optimization. They suggest an iterative process: initial IC50 screening to identify promising candidates, followed by ESI-MS to monitor chemical modifications that enhance electrostatic/H-bond interactions, and finally, X-ray crystallography for detailed structural rationalization. Further studies are needed to confirm these findings across a broader range of protein-ligand systems.

Summary updated

Abstract

Aldose reductase is a NADP(H)-dependent enzyme, believed to be strongly implicated in the development of degenerative complications of Diabetes Mellitus. The search for specific inhibitors of this enzyme has thus become a major pharmaceutic challenge. In this study, we applied both X-ray crystallography and mass spectrometry to characterize the interactions between aldose reductase and four representative inhibitors: AminoSNM, Imirestat, LCB3071, and IDD384. If crystallography remains obviously the only way to get an extensive description of the contacts between an inhibitor and the enzymatic site, the duration of the crystallographic analysis makes this technique incompatible with high throughput screenings of inhibitors. On the other hand, dissociation experiments monitored by mass spectrometry permitted us to evaluate rapidly the relative gas-phase stabilities of the aldose reductase-inhibitor noncovalent complexes. In our experiments, dissociation in the gas-phase was provoked by increasing the accelerating voltage of the ions (Vc) in the source-analyzer interface region: the Vc value needed to dissociate 50% of the noncovalent complex initially present (Vc50) was taken as a gas-phase stability parameter of the enzyme-inhibitor complex. Interestingly, the Vc50 were found to correlate with the energy of the electrostatic and H-bond interactions involved in the contact aldose reductase/inhibitor (Eel-H), computed from the crystallographic model. This finding may be specially interesting in a context of drug development. Actually, during a drug design optimization phase, the binding of the drug to the target enzyme is often optimized by modifying its interatomic electrostatic and H-bond contacts; because they usually depend on a single atom change on the drug, and are easier to introduce than the hydrophobic interactions. Therefore, the Vc50 may help to monitor the chemical modifications introduced in new inhibitors. X-ray crystallography is clearly needed to get the details of the contacts and to rationalize the design. Nevertheless, once the cycle of chemical modification is engaged, mass spectrometry can be used to select a priori the drug candidates which are worthy of further crystallographic investigation. We thus propose to use the two techniques in a complementary way, to improve the screening of large collections of inhibitors.
BibTeX
@article{rogniaux1999binding,
  author = {Hélène Rogniaux and Alain Van Dorsselaer and Patrick Barth and J.F. Biellmann and J. Barbanton and M. Van Zandt and Bernard Chevrier and Eduardo Howard and A. Mitschler and Noëlle Potier and Ludmila Urzhumtseva and D. Moras and A. Podjarny},
  title = {{Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies}},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {1999},
  doi = {10.1016/s1044-0305(99)00030-6},
}

Loading related content...

Figure